PHAT
Phathom Pharmaceuticals, Inc.15.24
+0.55+3.74%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
1.08BP/E (TTM)
-Basic EPS (TTM)
-3.76Dividend Yield
0%Recent Filings
10-K
FY2025 results
Phathom Pharmaceuticals drove FY2025 revenue to $175M from VOQUEZNA products, up sharply from $55M in FY2024, with most sales from GERD indications amid growing prescriptions topping 1.1M since launch. Q4 momentum built on prescriber adoption and 80% commercial payer access, yet net loss narrowed to $221M from $334M as gross profit swelled to $153M. Debt stands at $216M under Hercules terms maturing 2027, with $130M cash supporting profitability push in Q3 2026. Restructuring trimmed 6% of staff for efficiency. Supply risks linger for clarithromycin in TRIPLE PAK.
8-K
Q4 revenues $57.6M, 2026 profitability eyed
Phathom Pharmaceuticals reported Q4 2025 net revenues of $57.6 million, up from $29.7 million a year ago, with full-year 2025 hitting $175.1 million—a 217% surge. Sales force realignment boosted VOQUEZNA prescriptions 24% to 273,000 in Q4, while non-GAAP operating expenses dropped to $50.3 million. Cash burn slowed sharply. Guides $320–$345 million revenues for 2026, targeting operating profitability from Q3.
8-K
Prices $130M stock offering
Phathom Pharmaceuticals priced a $130 million public offering of 6.875 million common shares at $16.00 and pre-funded warrants for 1.25 million shares, with underwriters led by Guggenheim and Cantor gaining a 30-day option for 1.22 million more shares. Net proceeds, potentially $150 million if exercised in full, target working capital, commercialization, and R&D. Closing set for January 9, 2026, pending customary conditions. Market risks loom.
8-K
Phathom's strong Q4 prelims
Phathom Pharmaceuticals released preliminary Q4 2025 results on January 7, 2026, showing net revenues of ~$57-58M and full-year ~$174.5-175.5M, with VOQUEZNA surpassing 1M U.S. prescriptions since launch. GAAP opex hit ~$59-61M quarterly, non-GAAP ~$51-53M excluding $8M stock comp; cash ended at ~$130M. Path to profitability targets H2 2026, excluding stock comp. Cash burn slowed sharply.
8-K
First patient dosed in EoE trial
Phathom Pharmaceuticals dosed the first patient in its Phase 2 pHalcon EoE-201 trial on November 4, 2025, testing VOQUEZNA 20 mg tablets against placebo in 80 adults with eosinophilic esophagitis over 12 weeks, followed by a 12-week extension. Topline results are expected in 2027. Trial advances VOQUEZNA into a new indication. Risks include enrollment delays or negative data.
IPO
Employees
Sector
Industry
GOSS
Gossamer Bio, Inc.
3.56-0.23
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MIRM
Mirum Pharmaceuticals, Inc.
67.05+2.95
PHGE
BiomX Inc.
1.55-0.18
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
PHVS
Pharvaris N.V.
24.72+0.82
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
VRNA
Verona Pharma plc
106.91+0.00